Show simple item record

dc.contributor.authorLi, SW
dc.contributor.author李少伟
dc.contributor.authorZhang, J
dc.contributor.author张军
dc.contributor.authorLi, YM(Beijing Wantai Biological Pharmacy Enterprise Co., )
dc.contributor.authorOu, SH
dc.contributor.authorHuang, GY(Center of Disease Control, Guangxi Autonomous Region)
dc.contributor.authorHe, ZQ
dc.contributor.authorGe, SX
dc.contributor.author葛胜祥
dc.contributor.authorXian, YL(Beijing Wantai Biological Pharmacy Enterprise Co., )
dc.contributor.authorPang, SQ(Beijing Wantai Biological Pharmacy Enterprise Co.)
dc.contributor.authorNg, MH
dc.contributor.authorXia, NS
dc.contributor.author夏宁邵
dc.date.accessioned2011-10-03T13:12:08Z
dc.date.available2011-10-03T13:12:08Z
dc.date.issued2005
dc.identifier.citationVaccine. 2005 Apr 22;23(22):2893-901.zh_CN
dc.identifier.issn0264-410X
dc.identifier.urihttp://dx.doi.org/doi:http://www.sciencedirect.com/science/article/pii/S0264410X0400920X
dc.identifier.urihttps://dspace.xmu.edu.cn/handle/2288/10822
dc.description.abstractIt was evaluated its antigenicity, immunogenicity and efficacy of a candidate recombinant hepatitis E virus (HEV) vaccine, referred hitherto as HEV 239 vaccine. The vaccine peptide has a 26 amino acids extension from the N terminal of another peptide, E2, of the HEV capsid protein, which has been shown to protect monkeys against HEV infection previously. The vaccine peptide is similar as E2 in that: first, the vaccine peptide migrates predominantly as dimer in SDS-PAGE and it is dissociated into monomers by heating; second, its dimeric form of which predominantly recognized by HEV reactive human serum; and third, it shows the same pattern of reaction as E2 with a panel of eight monoclonal antibodies that had been raised against E2. In contrast to E2, the vaccine peptide aggregates to form particles of 13 nm mean radius, and consequently, it is more than 240 times more immunogenic than E2. Using alum as adjuvant, immunizing dose determined in mice was 80-250 ng for the vaccine and > 60 mu g for E2. Rhesus monkeys twice vaccinated with a 10 mu g or a 20 mu g formulation of this vaccine showed essentially the same antibody response, whereas the response to a 5 mu g formulation was delayed but reached similar antibody levels. All the three vaccine formulations afford complete protection against infection with 10(4) genome equivalent dose of the homologous genotype 1 virus. At higher virus dose of 10(7), the same vaccine formulation partially protected against the infection and completely protected against hepatitis. The efficacy of the vaccine was essentially the same for the homologous genotype 1 virus and heterologous genotype 4 virus. (c) 2004 Elsevier Ltd. All rights reserved.zh_CN
dc.language.isoenzh_CN
dc.publisherELSEVIER SCI LTDzh_CN
dc.subjecthepatitis E viruszh_CN
dc.subjectvaccinezh_CN
dc.subjectparticulatezh_CN
dc.subjectefficacyzh_CN
dc.subjectpre-clinicalzh_CN
dc.titleA bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primateszh_CN
dc.typeArticlezh_CN


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record